Chief Executive Officer
Sean has over 30 years of experience in the pharmaceutical industry. He started his career in sales and market research roles with A H Robins and progressed through local marketing to various Senior Global Marketing roles with Ferring Pharmaceutical and was most recently General Manager of the Ferring’s UK and Ireland Operation. He has been Director of Commercial Operations for the C&P Group since 2021. Sean is a non-Executive Director on various Boards within the C&P Group and was until recently interim CEO of the Finish company Rokote Oy and is Chairman of the Board and General Manager of the UK company Trizell Ltd.
Educated at the Coventry University and the University of London in Material Technology and Marketing respectively.
Chief Executive Officer
Sean has over 30 years of experience in the pharmaceutical industry. He started his career in sales and market research roles with A H Robins and progressed…
CEO, Amring USA
President and CEO of Amring Pharmaceuticals Inc. in USA with 5+ years building Amring from startup in the USA and a total of 19 years in the pharmaceutical industry. Daniel was graduated with a Bachelors degree in chemical engineering from Princeton University, with an MBA from Rutgers University in New Jersey, and from the Officers Basic Course in the U.S. Army Field Artillery School in Oklahoma. He has 38 years of experience starting, restructuring, acquiring and improving businesses in the pharmaceutical, consumer health, food and consumer products, environmental management, and strategic consulting fields. Daniel has progressed through large, small, and turnaround companies including Endo Pharmaceuticals, Procter and Gamble, Nabisco, KPMG, SmithKline Beecham, Axcentria, and the US Army.
CEO, Pharma Services
CEO of Pharmaceutical Services group at Sever Life Sciences, Kenneth brings 25 years of pharmaceutical industry experience. Kenneth joined QPharma as CEO in 2009 and has served in several roles at Nordic Group, including SVP of Technical operations and Strategic Development. Prior to this, he spent eight years in several international positions with Xellia pharmaceuticals, incl GM China, and five years in different technical roles with Novo Nordisk. Kenneth holds an MSc in chemical engineering from the technical university of Denmark (DTU) and an executive MBA from HEC in Paris.
CEO, Izvarino Pharma
General manager of Izvarino Pharma LLC from 2010 to the present. General manager of Nanopharma Development from 2016 to the present. In the Russian pharmaceutical business since 1996. Present activities together with the Russian team introduced to the Russian market the company Astellas Pharma and carried out the development of the Russian company Alium. Medical Doctor, pharmacologist (PhD), DBA (Higher School of Economics, Moscow), Stanford graduate school of business (Stanford, CA).
Aernout de Bruijne
Director of Finance & Operations Planning
Director of Finance & Operating Planning working in the pharmaceutical industry over nine years and prior to this held several international positions in the software industry, over a ten year period for Informatica, a US public IT company taken private, as well as the private IT company Information Builders, overseeing international finance functions within Europe and Australia. Holding a bachelor degree in business economics and a MBA from NCOI.
Group Human Resources & Corporate Communications Officer
Shahed has over 30 years of in HR experience in a wide range of industries holding various Country , Regional, European and Global HR roles. Some of the Companies he has worked for include Wyeth Pharmaceuticals, Novartis Pharmaceuticals, General Electric and Ferring Pharmaceuticals.
He is extremely passionate about Diversity & Inclusion having held the position of Global Director, Diversity & Inclusion prior to joining SEVER.
Shahed holds a Master of Arts in Strategic Human Resource Management from Kingston University, London.